Erlotinib Recruiting Phase 2 Trials for EGFR Positive Non-small Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03126799A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)